<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117569</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1701</org_study_id>
    <nct_id>NCT03117569</nct_id>
  </id_info>
  <brief_title>Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients</brief_title>
  <acronym>SMART-C</acronym>
  <official_title>A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if treatment monitoring schedule for chronic HCV
      patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.

      Data has shown that direct acting antiviral (DAA) regimen of glecaprevir (300mg)/pibrentasvir
      (120mg), a protease inhibitor and NS5A inhibitor respectively , provides key features for HCV
      treatment simplification.

      Eligible participants (naïve pre-cirrhosis chronic HCV patients) will be randomized (1:2) to
      the standard or simplified monitoring arm and will receive treatment for 8 weeks.

      One post treatment visit will be conducted 12 weeks after the final dose of study medication
      to evaluate the proportion of patients with undetectable HCV RNA at this timepoint (SVR12).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The capacity to scale-up interferon-free DAA therapy would be enhanced by simplified
      treatment monitoring strategies. The &quot;next generation&quot; DAA regimen of glecaprevir
      (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor, provides key features
      for HCV treatment simplification, including on-treatment monitoring: 1) pangenotypic activity
      with extremely high efficacy (SVR&gt;95%); 2) no relationship between time to undetectable HCV
      RNA and SVR; 3) minimal drug-related toxicity; 4) ease of dosing (three pills once daily);
      and short duration (8 weeks in non-cirrhosis and 12 weeks in cirrhosis for treatment naïve
      patients). In phase II and III clinical trials in participants without cirrhosis, 8 weeks of
      glecaprevir (300mg)/pibrentasvir (120mg) has provided intention-to-treat SVR rates of 99.1%,
      98%, 97%, and 93.1% in genotype 1, 2, 3, and 4-6 populations, respectively.

      Current standard on-treatment monitoring in clinical trials involves clinic-based visits
      every 4 weeks. In the DAA era where treatments are highly tolerable, effective and short
      duration, this intensive monitoring strategy may no longer be required. A simplified
      on-treatment monitoring strategy is hypothesised to be non-inferior to the standard clinical
      trial on treatment monitoring strategy. If successful, a simplified on-treatment monitoring
      strategy is likely to be highly attractive to patients, clinicians and health care payers. It
      has the potential to improve the rapid scale up of treatment providing population level
      benefits in the reduction of global hepatitis C disease burden.

      This study will be conducted as a Phase IIIb, randomised, controlled, multicentre,
      international trial.

      There will be a maximum screening period of 6 weeks prior to Baseline. Eligible patients will
      be randomised into one of two on-treatment monitoring strategies; standard clinical trial
      monitoring (4-weekly on-treatment visits) vs simplified monitoring (no on-treatment visits).
      Randomisation will be 1:2 (standard vs simplified) and all participants will receive
      treatment with glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks.

      All participants will attend the clinic for screening and baseline visit. Randomisation will
      occur at the baseline visit.

      The two on-treatment monitoring strategies will differ as follows:

        -  Standard monitoring arm participants will have on-treatment clinic visits at weeks 4 and
           8 (EoT).

        -  Simplified monitoring arm participants will have no on-treatment clinic visits.

      Study nurse phone contact will also be made to participants in BOTH arms 1-2 days prior Week
      4 and EoT (Week 8) visits to provide standardized reporting of adverse events, concomitant
      medication and adherence. One post treatment clinic visit will be conducted at SVR12 (week
      20) for all participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV RNA (ITT population)</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Proportion of participants with undetectable HCV RNA based on ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA (mITT population)</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Proportion of participants with undetectable HCV RNA based on mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment and study visits adherence</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Proportion adherent to treatment and study visits (on-treatment adherence and early treatment discontinuation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Change in health-related quality of life during treatment (measured by EQ-5D-3L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV resistance</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Sustained Virological Response (HCV RNA undetectable 12 weeks post-treatment) in participants with and without baseline Resistance Associated Substitutions (RAS) and RAS distribution in participants with virological failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient treatment satisfaction</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Patient treatment satisfaction measured by a questionnaire applied to all participants.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Common adverse events (safety outcome)</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Proportion of patients with common adverse events (reported in greater than 5%).</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe/life threatening adverse events (safety outcome)</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Proportion of patients with at least one severe or potentially life threatening (grade 3 or 4) adverse event.</description>
  </other_outcome>
  <other_outcome>
    <measure>Provider acceptability of simplified monitoring strategy (Exploratory outcome)</measure>
    <time_frame>12 weeks post end of treatment (SVR12)</time_frame>
    <description>Provider acceptability of simplified monitoring strategy measured by study specific questionnaire completed by each site Principal Investigator and the primary Research Nurse.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Standard monitoring schedule</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simplified monitoring schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glecaprevir (300mg)/pibrentasvir (120mg)</intervention_name>
    <description>glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks</description>
    <arm_group_label>Standard monitoring schedule</arm_group_label>
    <arm_group_label>Simplified monitoring schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have voluntarily signed the informed consent form.

          2. 18 years of age or older.

          3. Chronic HCV infection as defined by anti-HCV antibody or HCV RNA detection for greater
             than 6 months.

          4. HCV RNA plasma ≥ 10,000 IU/ml at screening.

          5. HCV genotype 1-6.

          6. HCV treatment naïve (no prior treatment with an approved or investigation anti-HCV
             medication).

          7. Stage F0-3, based on: hepatic elastography &lt;12.5 kPa on Fibroscan® or APRI &lt;1.0.

          8. If co-infection with HIV is documented, the subject must meet the following criteria:

               -  ART naïve with CD4 T cell count &gt;500 cells/mm3; OR

               -  On a stable ART regimen (containing only permissible ART - see protocol section
                  3.2) for &gt;8 weeks prior to screening visit, with CD4 T cell count &gt;200 cells/mm3
                  and a plasma HIV RNA level below the limit of detection.

          9. Negative pregnancy test at screening and baseline (females of childbearing potential
             only).

         10. All fertile females must be using effective contraception during treatment and during
             the 30 days after treatment end.

        Exclusion Criteria:

          1. History of any of the following:

               1. Clinically significant illness (other than HCV) or any other major medical
                  disorder that may interfere with the participant treatment, assessment or
                  compliance with the protocol; participants currently under evaluation for a
                  potentially clinically significant illness (other than HCV) are also excluded.

               2. Clinical hepatic decompensation (i.e. ascites, encephalopathy or variceal
                  haemorrhage).

               3. Solid organ transplant.

               4. History of severe, life-threatening or other significant sensitivity to any
                  excipients of the study drugs.

          2. Any of the following lab parameters at screening:

               1. ALT &gt; 10 x ULN

               2. AST &gt; 10 x ULN

               3. Direct bilirubin &gt; ULN

               4. Platelets &lt; 90,000/μL (cells/mm3) if Fibroscan® &lt;12.5 kPa OR &lt; 150,000/μL
                  (cells/mm3) if Fibroscan® is unavailable and patient is included with APRI &lt;1

               5. Creatinine clearance (CLcr) &lt; 50 mL/min

               6. Haemoglobin &lt; 12g/dL for males; &lt;11g/dL for females

               7. Albumin &lt; LLN

               8. INR &gt; 1.5 ULN unless subject has known haemophilia or is stable on an
                  anticoagulant regimen affecting INR

          3. Pregnant or breastfeeding female.

          4. HBV infection (HBsAg positive).

          5. Use of prohibited concomitant medications as described in protocol section 5.2.

          6. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone
             equivalent &gt; 10 mg/day for &gt;2 weeks).

          7. Therapy with any anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of
             study drug.

          8. Any investigational drug ≤6 weeks prior to the first dose of study drug.

          9. Ongoing severe psychiatric disease as judged by the treating physician.

         10. Positive result of a urine drug screen at the Screening Visit for opiates,
             barbiturates, amphetamines, cocaine, benzodiazepines, phencyclidine, propoxyphene, or
             alcohol, with the exception of a positive result (including methadone) associated with
             documented short-term use or chronic stable use of a prescribed medication in that
             class.

         11. Injecting drug use within the previous six months.

         12. Inability or unwillingness to provide informed consent or abide by the requirements of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Dore</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute, University of New South Wales Sydney, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pip Marks</last_name>
    <phone>+61293850886</phone>
    <email>pmarks@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Curry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ira Jacobson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Muir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SSM Health Dean Medical Group</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Levin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Sydney Doctors</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Baker, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gail Matthews, MBChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Bloch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Shaw, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stuart Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Thompson, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lair Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edward Tam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(G.I.R.I.) GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alnoor Ramji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Borgia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keith Tsoi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M57 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordan Feld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Louise Vachon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Hezode</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Bourliere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karine Lacombe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>zibp - Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Axel Baumgarten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for HIV and Hepatogastroenterology</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Mauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hanover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Markus Cornberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIM-Centrum fuer Interdisziplinaere Medizin GmbH</name>
      <address>
        <city>Münster</city>
        <zip>48143</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Christensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ed Gane, MBChB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calder Center</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Stedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Schultz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital - Universitaetsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nasser Semmo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Beat Müllhaupt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Graham Foster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kosh Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust (St Mary's Hospital)</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Graham Cooke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>No individual participant data will be shared. The results of the project will be presented at scientific meetings, and published in peer reviewed scientific literature. Sharing of data generated by this project is an essential part of our proposed activities and will be carried out in several different ways. We plan to make our results available to the community of scientists interested in recently acquired hepatitis C, community organisations representing the affected communities and participants. We also welcome collaboration with others who could make use of data and samples.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

